Anterior juxtascleral depot of anecortave acetate reduces IOP significantly

IOP can be reduced significantly by an anterior juxtascleral depot of anecortave acetate, according to study results presented on a poster at this year's meeting of the Association for Research in Vision and Ophthalmology.

Tiago S. Prata, MD conducted a prospective, non-randomized open-labelled trial on 25 eyes of uncontrolled glaucoma patients with a mean IOP of 30.9±9.2 mmHg. Dr Prata injected a single anterior juxtascleral depot of 30 mg of anecortave acetate and then assessed the eyes for the following three months. No major complications were recorded.

Mean IOP decreased to 20.9±7.5 mmHg at the first month. At the second month, IOP had increased slightly to 21.5±7.6 mmHg; in the third month, mean IOP dropped again to 19.1±5.2 mmHg.

Thus the researchers concluded that a single injection of anecortave acetate was sufficient to reduce IOP for a period of at least three months.